A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
CV Sciences, Inc. (“CV Sciences,” the “Company,” “we,” “our” or “us”) is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (“B2B”) to business-to-consumer (“B2C”). Our +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 14M | 16M | 16M | 16M | 20M | 24M |
| Net Income | -1.5M | -2.4M | 3.1M | -9.1M | -16M | -22M |
| EPS | $0.00 | $-0.01 | $0.02 | $-0.07 | $-0.14 | $-0.22 |
| Free Cash Flow | -335K | -879K | 2.3M | -1.9M | -7.5M | -8.4M |
| ROIC | -37.7% | -73.8% | 348.9% | -719.3% | -626.2% | -166.5% |
| Gross Margin | 47.0% | 45.6% | 44.3% | 34.2% | 43.0% | 45.1% |
| Debt/Equity | 0.91 | 0.81 | 0.24 | -3.54 | 0.43 | 0.76 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -1.0M | -2.2M | 3.4M | -6.8M | -18M | -23M |
| Operating Margin | -7.2% | -13.9% | 21.0% | -42.3% | -92.0% | -92.5% |
| ROE | -96.0% | -101.9% | 106.9% | - | -439.0% | -198.8% |
| Shares Outstanding | 184M | 239M | 155M | 130M | 111M | 101M |
CV Sciences, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 42.4%. At current prices, the estimated annualized return to fair value is -37.6%.
CV Sciences, Inc. (CVSI) has a 5-year average return on invested capital (ROIC) of -120.2%. This is below average and may indicate limited pricing power.
CV Sciences, Inc. (CVSI) has a market capitalization of $6M. It is classified as a small-cap stock.
CV Sciences, Inc. (CVSI) does not currently pay a regular dividend.
CV Sciences, Inc. (CVSI) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CV Sciences, Inc. (CVSI) reported annual revenue of $16 million in its most recent fiscal year, based on SEC EDGAR filings.
CV Sciences, Inc. (CVSI) has a net profit margin of -15.2%. The company is currently unprofitable.
CV Sciences, Inc. (CVSI) generated $-879 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CV Sciences, Inc. (CVSI) has a debt-to-equity ratio of 0.81. This indicates moderate leverage.
CV Sciences, Inc. (CVSI) reported earnings per share (EPS) of $-0.01 in its most recent fiscal year.
CV Sciences, Inc. (CVSI) has a return on equity (ROE) of -101.9%. A negative ROE may indicate losses or negative equity.
CV Sciences, Inc. (CVSI) has a 5-year average gross margin of 42.4%. This indicates decent pricing power.
The Ledger Terminal provides 13 years of financial data for CV Sciences, Inc. (CVSI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CV Sciences, Inc. (CVSI) has a book value per share of $0.01, based on its most recent annual SEC filing.